Tags

Type your tag names separated by a space and hit enter

[The polypill: optimal strategy for reduction of cardiovascular disease].
Ned Tijdschr Geneeskd. 2005 Jul 30; 149(31):1740.NT

Abstract

Treating all persons above 55 years of age with a polypill for primary and secondary cardiovascular-disease prevention may reduce cardiovascular events by more than 80%. This strategy is expected to be cost-effective and the associated risk of side effects is estimated to be low.

Authors+Show Affiliations

Nathoe HM
Universitair Medisch Centrum Utrecht, afd. Cardiologie, Postbus 85.500, 3508 GA Utrecht.
Doevendans PA
No affiliation info available

MeSH

Antihypertensive AgentsAspirinCardiovascular DiseasesCost-Benefit AnalysisDrug CombinationsFemaleFolic AcidHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsPrimary Prevention

Pub Type(s)

English Abstract
Journal Article

Language

dut

PubMed ID

16114290

Citation

Nathoe, H M., and P A F M. Doevendans. "[The Polypill: Optimal Strategy for Reduction of Cardiovascular Disease]." Nederlands Tijdschrift Voor Geneeskunde, vol. 149, no. 31, 2005, p. 1740.
Nathoe HM, Doevendans PA. [The polypill: optimal strategy for reduction of cardiovascular disease]. Ned Tijdschr Geneeskd. 2005;149(31):1740.
Nathoe, H. M., & Doevendans, P. A. (2005). [The polypill: optimal strategy for reduction of cardiovascular disease]. Nederlands Tijdschrift Voor Geneeskunde, 149(31), 1740.
Nathoe HM, Doevendans PA. [The Polypill: Optimal Strategy for Reduction of Cardiovascular Disease]. Ned Tijdschr Geneeskd. 2005 Jul 30;149(31):1740. PubMed PMID: 16114290.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The polypill: optimal strategy for reduction of cardiovascular disease]. AU - Nathoe,H M, AU - Doevendans,P A F M, PY - 2005/8/24/pubmed PY - 2005/9/24/medline PY - 2005/8/24/entrez SP - 1740 EP - 1740 JF - Nederlands tijdschrift voor geneeskunde JO - Ned Tijdschr Geneeskd VL - 149 IS - 31 N2 - Treating all persons above 55 years of age with a polypill for primary and secondary cardiovascular-disease prevention may reduce cardiovascular events by more than 80%. This strategy is expected to be cost-effective and the associated risk of side effects is estimated to be low. SN - 0028-2162 UR - https://www.unboundmedicine.com/medline/citation/16114290/[The_polypill:_optimal_strategy_for_reduction_of_cardiovascular_disease]_ DB - PRIME DP - Unbound Medicine ER -